-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Top 5 Health Care Stocks That May Plunge In March
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here's the latest list of major overbought players in this sector.
The Pennant Group, Inc. (NASDAQ:PNTG)
- On Feb. 28, Pennant posted better-than-expected quarterly sales. "We are pleased with our strong finish to 2023 and continued momentum as we enter 2024," said Brent Guerisoli, Pennant's Chief Executive Officer. "By executing on our five key focus areas--leadership development, clinical excellence, employee engagement, margin improvement, and growth--we made steady gains throughout 2023 and solidly delivered on earnings expectations, even after increasing guidance during the year." The company's stock gained around 18% over the past month and has a 52-week high of $20.50 .
- RSI Value: 90.15
- PNTG Price Action: Shares of Pennant Group gained 1.7% to close at $19.84 on Wednesday.
Mesoblast Limited (NASDAQ:MESO)
- On March 25, the FDA informed Mesoblast that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The company's stock gained around 54% over the past five days and has a 52-week high of $10.24.
- RSI Value: 71.74
- MESO Price Action: Shares of Mesoblast dipped 11.2% to close at $3.49 on Wednesday.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
- On March 21, ARS Pharmaceuticals reported a narrower-than-expected fourth-quarter loss. The company's stock gained around 13% over the past five days and has a 52-week high of $10.20.
- RSI Value: 70.11
- SPRY Price Action: Shares of ARS Pharmaceuticals fell 0.4% to close at $9.96 on Wednesday.
Neuronetics, Inc. (NASDAQ:STIM)
- On March 25, NeuroStar Advanced Therapy received the FDA clearance as first-line add-on treatment for adolescents with depression. The company's stock jumped around 62% over the past month and has a 52-week high is $4.99.
- RSI Value: 72.16
- STIM Price Action: Shares of Neuronetics gained 0.8% to close at $4.80 on Wednesday.
Inozyme Pharma, Inc. (NASDAQ:INZY)
- On March 26, Inozyme Pharma announced that it will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency, and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency. The company's stock jumped around 22% over the past five days and has a 52-week high of $7.56.
- RSI Value: 71.56
- INZY Price Action: Shares of Inozyme Pharma climbed 9% to close at $7.39 on Wednesday.
Read More: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年3月28日,医疗保健行业的五只股票可能会向将动量视为交易决策关键标准的投资者发出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI 是一种动量指标,它比较股票在价格上涨的日子和价格下跌的日子的走势。与股票的价格走势相比,它可以让交易者更好地了解股票在短期内的表现。根据Benzinga Pro的数据,当相对强弱指数高于70时,资产通常被视为超买。
Here's the latest list of major overbought players in this sector.
以下是该行业主要超买参与者的最新名单。
The Pennant Group, Inc. (NASDAQ:PNTG)
彭南特集团有限公司(纳斯达克股票代码:PNTG)
- On Feb. 28, Pennant posted better-than-expected quarterly sales. "We are pleased with our strong finish to 2023 and continued momentum as we enter 2024," said Brent Guerisoli, Pennant's Chief Executive Officer. "By executing on our five key focus areas--leadership development, clinical excellence, employee engagement, margin improvement, and growth--we made steady gains throughout 2023 and solidly delivered on earnings expectations, even after increasing guidance during the year." The company's stock gained around 18% over the past month and has a 52-week high of $20.50 .
- RSI Value: 90.15
- PNTG Price Action: Shares of Pennant Group gained 1.7% to close at $19.84 on Wednesday.
- 2月28日,彭南公布的季度销售额好于预期。彭南特首席执行官布伦特·盖里索利表示:“我们对2023年的强劲表现以及进入2024年的持续势头感到满意。”“通过执行我们的五个关键重点领域——领导力发展、临床卓越表现、员工敬业度、利润率提高和增长——我们在2023年全年取得了稳步增长,尽管年内提高了预期。”该公司的股票在过去一个月中上涨了约18%,并且 52 周高点为 20.50 美元 。
- RSI 值:90.15
- PNTG价格走势:彭南特集团股价周三上涨1.7%,收于19.84美元。
Mesoblast Limited (NASDAQ:MESO)
Mesoblast Limited(纳斯达克股票代码:MESO)
- On March 25, the FDA informed Mesoblast that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The company's stock gained around 54% over the past five days and has a 52-week high of $10.24.
- RSI Value: 71.74
- MESO Price Action: Shares of Mesoblast dipped 11.2% to close at $3.49 on Wednesday.
- 3月25日,美国食品药品管理局告知Mesoblast,经过进一步考虑,其3期研究 MSB-GVHD001 的现有临床数据似乎足以支持针对类固醇难治性急性移植物抗宿主病(sr-AGVHD)儿科患者的remestemcel-L的拟议生物制剂许可申请(BLA)。该公司的股票在过去五天中上涨了约54%, 创下 52 周新高 为10.24美元。
- RSI 值:71.74
- MESO价格走势:周三,Mesoblast的股价下跌11.2%,收于3.49美元。
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
ARS 制药公司(纳斯达克股票代码:SPRY)
- On March 21, ARS Pharmaceuticals reported a narrower-than-expected fourth-quarter loss. The company's stock gained around 13% over the past five days and has a 52-week high of $10.20.
- RSI Value: 70.11
- SPRY Price Action: Shares of ARS Pharmaceuticals fell 0.4% to close at $9.96 on Wednesday.
- 3月21日,ARS制药公司公布的第四季度亏损低于预期。该公司的股票在过去五天中上涨了约13%,并且 52 周高点 为10.20美元。
- 相对强弱指数值:70.11
- SPRY价格走势:周三,ARS制药公司股价下跌0.4%,收于9.96美元。
Neuronetics, Inc. (NASDAQ:STIM)
Neuronetics, Inc.(纳斯达克股票代码:STIM)
- On March 25, NeuroStar Advanced Therapy received the FDA clearance as first-line add-on treatment for adolescents with depression. The company's stock jumped around 62% over the past month and has a 52-week high is $4.99.
- RSI Value: 72.16
- STIM Price Action: Shares of Neuronetics gained 0.8% to close at $4.80 on Wednesday.
- 3月25日,NeuroStar高级疗法作为抑郁症青少年的一线附加疗法获得了美国食品药品管理局的批准。该公司的股票在过去一个月中上涨了约62%,创52周高点为4.99美元。
- RSI 值:72.16
- STIM价格走势:周三,Neuronetics的股价上涨0.8%,收于4.80美元。
Inozyme Pharma, Inc. (NASDAQ:INZY)
Inozyme Pharma, Inc.(纳斯达克股票代码:INZY)
- On March 26, Inozyme Pharma announced that it will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency, and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency. The company's stock jumped around 22% over the past five days and has a 52-week high of $7.56.
- RSI Value: 71.56
- INZY Price Action: Shares of Inozyme Pharma climbed 9% to close at $7.39 on Wednesday.
- 3月26日,Inozyme Pharma宣布,它将讨论其正在进行的针对患有 ABCC6 的成年人的 INZ-701 1/2 期试验以及正在进行的 ENPP1 缺乏成人 INZ-701 的 1/2 期试验的主要数据。该公司的股票在过去五天中上涨了约22%, 创下 52 周新高 7.56 美元。
- RSI 值:71.56
- INZY价格走势:周三,Inozyme Pharma的股价上涨了9%,收于7.39美元。
Read More: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday
阅读更多: 进入周四,RH、Walgreens和3只股票值得关注
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧